Asia’s Sterile Manufacturing Landscape Is Changing: What Annex 1 Means for Manufacturers

Sterile manufacturing across Asia is entering a new phase.

As the region expands its capabilities in biologics, vaccines and complex injectable medicines, manufacturers are facing a parallel challenge: how do you increase manufacturing capacity while meeting increasingly sophisticated expectations around sterility assurance and contamination control?

The revised EU GMP Annex 1 for the Manufacture of Sterile Medicinal Products has brought this question into sharper focus.

While Annex 1 is a European GMP framework, its influence extends far beyond Europe. For Asian manufacturers supplying international markets Ñ particularly those operating within PIC/S-aligned regulatory environments Ñ its principles are highly relevant to how sterile manufacturing facilities are designed, operated and modernised.

And the changes are already visible across Asia.

From new sterile fill-finish capacity in Singapore to large-scale biologics manufacturing in South Korea, companies are investing in automation, barrier technologies, flexible manufacturing and more integrated drug-product capabilities.

The question is no longer simply about compliance.

What will the next generation of sterile manufacturing in Asia look like?

Perhaps the biggest change reinforced by Annex 1 is the move from detecting contamination to preventing it.

Sterility assurance cannot depend on one cleanroom, one environmental monitoring programme or final-product testing.

Manufacturers need to consider the entire system:

Facility _ People _ Equipment _ Utilities _ Process _ Monitoring _ Final Product

This is where the Contamination Control Strategy (CCS) becomes important.

A strong CCS brings together facility design, personnel and material flows, cleaning and disinfection, environmental monitoring, utilities, equipment, process validation, maintenance and quality risk management.

Rather than asking:

“Does each individual system comply?”

manufacturers increasingly need to ask:

“How do all of these systems work together to prevent contamination?”

For older facilities, this may require reassessing established manufacturing practices.

For new facilities being developed across Asia, however, it creates an opportunity to design contamination control into the facility from day one.

This transformation is not theoretical.

Singapore provides a good example of how sterile manufacturing capability is becoming strategically important.

Thermo Fisher Scientific established a new sterile drug facility in Singapore as part of an expansion of its global sterile fill-finish network. The facility was designed around high-speed sterile filling, with cleanrooms, laboratories and supporting infrastructure for pharmaceutical and vaccine manufacturing.

The company stated that the facility could manufacture up to 30 million sterile doses per month when announced.

The investment was positioned not only as additional manufacturing capacity, but also as a way to strengthen pharmaceutical and vaccine supply resilience in Asia-Pacific.

Singapore's ecosystem also includes companies developing different types of fill-finish capability.

Esco Aster, for example, offers small-batch aseptic fill-finish services supporting clinical and small commercial requirements, demonstrating another important direction for the industry: flexibility rather than simply scale.

This distinction will become increasingly important.

Not every future injectable medicine will require enormous commercial filling lines.

Advanced therapies, personalised medicines and specialised biologics may instead require smaller batches, faster changeovers and more flexible manufacturing environments.

People remain one of the largest potential sources of contamination in an aseptic environment.

Every time an operator needs to intervene in a critical manufacturing zone, additional risk is introduced.

This is helping accelerate adoption of technologies designed to create greater separation between operators and exposed sterile products.

Among them:

Restricted Access Barrier Systems (RABS)

Isolators

Closed processing systems

Automated material transfer

Robotic handling

Automated filling systems

The objective is straightforward:

Fewer interventions. Fewer opportunities for contamination.

Asia in Practice: South Korea

South Korea offers a particularly interesting example.

Korea Vaccine publicly describes sterile fill-finish capabilities using both RABS and isolator technology for vial manufacturing.

Its disclosed capabilities include liquid and lyophilised vial filling as well as prefilled syringe manufacturing.

This is a useful example of the technology choices manufacturers are increasingly making.

RABS can provide additional separation between operators and the critical processing environment, while isolators can take that separation significantly further.

As Annex 1 continues influencing global sterile manufacturing expectations, decisions around RABS versus isolators will become increasingly strategic for manufacturers planning new capacity.

4. RABS, Isolators Ñ or Something Beyond Both?

There is no universal answer to which barrier technology every manufacturer should adopt.

The decision depends on factors such as:

Product characteristics

Batch size

Filling speed

Changeover frequency

Decontamination requirements

Facility design

Capital expenditure

Manufacturing flexibility

A high-volume vaccine filling operation may have very different requirements from a facility producing small batches of specialised biologics.

But the overall direction is becoming clearer.

The future of aseptic processing involves reducing direct human interaction with exposed sterile product wherever practical.

And this leads naturally to the next development.

Imagine an aseptic filling line where operators rarely Ñ or never Ñ need to physically interact with the critical filling environment.

This is increasingly possible as robotics and automation develop.

Robotic systems can potentially support:

Component handling

Filling

Stoppering

Loading and unloading

Material transfer

Inspection

The result could be highly automated aseptic manufacturing environments with dramatically fewer manual interventions.

This matters not only for contamination control.

Automation can potentially deliver:

Greater consistency

Reduced operator-dependent variability

Improved repeatability

Better process data

More efficient small-batch manufacturing

For Asia, the opportunity is particularly interesting.

New facilities do not necessarily need to replicate manufacturing models developed decades ago.

They can potentially leap directly toward more closed, automated and digitally connected sterile manufacturing.

Another shift is taking place.

Historically, much of the attention around Asian biopharmaceutical manufacturing focused on drug-substance capacity Ñ bioreactors, upstream processing, downstream purification and production scale.

But producing the biologic is only part of the journey.

It still needs to become a finished sterile drug product.

That means formulation, aseptic filling, potentially lyophilisation, inspection, packaging and release.

Some of Asia's largest CDMOs are therefore increasingly positioning drug product alongside drug substance.

Samsung Biologics, for example, offers services extending from biologics development and manufacturing through to final aseptic fill-finish.

This reflects a broader industry shift toward more integrated manufacturing models.

For pharmaceutical companies, the attraction is clear:

Drug Substance _ Drug Product _ Fill-Finish

can increasingly be managed within a connected manufacturing network rather than through multiple disconnected suppliers.

For Asian CDMOs, fill-finish capability could therefore become an increasingly important competitive differentiator.

Environmental monitoring has always been fundamental to sterile manufacturing.

But collecting environmental data is no longer enough.

The real value comes from understanding what the data is telling manufacturers about their processes.

Instead of looking only at individual excursions, manufacturers can increasingly analyse:

Long-term environmental trends

Recurring contamination patterns

Location-specific risks

Intervention-related events

Process correlations

Early warning signals

This is where digitalisation could significantly change sterile manufacturing.

As environmental, process and equipment data become more connected, manufacturers may eventually move from simply detecting contamination events toward identifying conditions that indicate contamination risk is increasing.

In other words:

Monitoring tells you what happened.

Predictive manufacturing could help tell you what might happen next.

That could become one of the most important technological shifts in future sterile facilities.

Asia's sterile manufacturing challenge is also changing because the products themselves are changing.

The region's pharmaceutical industry is increasingly involved in manufacturing:

Monoclonal antibodies

Vaccines

Biosimilars

Antibody-drug conjugates

Cell and gene therapies

Other complex injectable medicines

These products can introduce very different manufacturing requirements.

An antibody-drug conjugate, for example, may introduce containment considerations alongside aseptic processing requirements.

A cell or gene therapy may require much smaller batch sizes and highly controlled manufacturing workflows.

A commercial monoclonal antibody may require significantly greater scale.

This means the future sterile manufacturing facility may need to achieve something that sounds contradictory:

Greater control and greater flexibility at the same time.

That challenge could drive demand for modular facilities, single-use systems, robotics and flexible filling technologies.

It is also important not to treat Asia as a single manufacturing ecosystem.

Different markets are developing different strengths.

Singapore is building on its position as a high-value pharmaceutical manufacturing hub, with multinational and local companies investing across biologics, vaccines and sterile manufacturing.

South Korea has developed significant large-scale biologics and CDMO capabilities, with companies such as Samsung Biologics expanding end-to-end manufacturing offerings.

China has developed an extensive biopharmaceutical manufacturing and outsourcing ecosystem.

India combines its established pharmaceutical and vaccine manufacturing base with growing investment in biologics and injectable manufacturing.

Japan continues to bring sophisticated pharmaceutical manufacturing capabilities alongside increasing activity in advanced therapies and regenerative medicine.

The opportunity is therefore not simply “more manufacturing in Asia.”

It is the development of different centres of excellence across the region.

And sterile manufacturing and fill-finish could become an increasingly important part of how these hubs differentiate themselves.

This may ultimately be the most important implication of Annex 1 for Asia.

Advanced sterile manufacturing should not be viewed purely as a regulatory cost.

It can become a competitive advantage.

When global pharmaceutical companies evaluate manufacturing partners, they increasingly need confidence in more than available capacity.

They need confidence in:

Sterility assurance

Quality systems

Regulatory readiness

Technology capability

Manufacturing flexibility

Process control

Data integrity

Supply reliability

A CDMO with advanced barrier technology, highly automated fill-finish, robust contamination-control systems and strong regulatory experience may therefore be able to compete on something much more valuable than price.

It can compete on manufacturing confidence.

Put these trends together and an interesting picture emerges.

The next generation of Asian sterile manufacturing facilities could be:

More closed

Greater adoption of isolators, RABS and closed processing technologies.

More automated

Fewer manual interventions in critical aseptic operations.

More flexible

Manufacturing designed for different products, formats and increasingly smaller batches.

More connected

Environmental, process, equipment and quality data integrated across manufacturing operations.

More predictive

Advanced analytics helping manufacturers identify risks before they become failures.

More contamination-resilient

Facilities designed around prevention rather than reaction.

The transition will not happen overnight.

Legacy facilities will continue to operate. Different products will require different manufacturing approaches. And every manufacturer will need to balance technological ambition with operational and economic realities.

But the direction of travel is becoming increasingly difficult to ignore.

Annex 1 is more than another regulatory requirement.

It reflects a broader transformation already underway across sterile pharmaceutical manufacturing.

Contamination control is becoming more integrated.

Human intervention is being reduced.

Barrier technologies are becoming more important.

Automation is expanding.

Environmental monitoring is becoming increasingly data-driven.

And fill-finish is becoming an increasingly strategic part of the biopharmaceutical manufacturing value chain.

The investments already being made by companies such as Thermo Fisher Scientific, Samsung Biologics, Korea Vaccine and Esco Aster illustrate different parts of this transition.

And Asia may still be at the beginning of it.

For years, much of the discussion around Asian pharmaceutical manufacturing centred on cost, scale and manufacturing capacity.

The next chapter could look very different.

The question is no longer simply:

Can Asia manufacture more?

It is:

Can Asia build the next generation of sterile manufacturing and fill-finish?

At Connexius Group, we believe this is a conversation worth bringing together.

Sterile Manufacturing & Fill-Finish Asia will bring together pharmaceutical and biopharmaceutical manufacturers, CDMOs, technology providers and industry experts to explore the technologies, strategies and manufacturing models shaping the future of aseptic production across Asia.

From Annex 1 and contamination control to barrier technologies, robotics, automation, fill-finish, environmental monitoring and next-generation facility design, Asia's sterile manufacturing transformation is only beginning.